Assessment and management of cannabis use disorders in primary care

BMJ (Online)

Volumn 340, Issue 7750, 2010, Pages 800-804

  Winstock, Adam R ^a   Ford, Chris ^b   Witton, John ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Skipton House ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; TETRAHYDROCANNABINOL DERIVATIVE;

ANXIETY DISORDER; APPETITE; BEHAVIOR THERAPY; CANNABIS ADDICTION; CIGARETTE SMOKING; CLINICAL ASSESSMENT; CLINICAL TRIAL; COGNITION; COGNITIVE THERAPY; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; DRUG ABSORPTION; DRUG INTOXICATION; HUMAN; LUNG CANCER; LUNG DISEASE; MEDICAL SPECIALIST; MEMORY; MENTAL DISEASE; MENTAL HEALTH; MOOD; MOTIVATION; OUTCOME ASSESSMENT; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SLEEP; SMOKING CESSATION; SYSTEMATIC REVIEW; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

EID: 77950685002     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c1571     Document Type: Review

References (29)

1. Hoare J. Drug misuse declared: findings from the 2008/09 British Crime Survey. Home Office, 2009.
2. Dennis M, Babor TF, Roebuck MC, Donaldson J. Changing the focus: the case for recognizing and treating cannabis use disorders. Addiction 2002;97:4-15. (Pubitemid 36013441)
3. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet 2009;374:1383-1391
4. Hardwick S, King L. Home Office Potency Study 2008. Home Office, 2008.
5. Department of Health, National Treatment Agency. Statistics from the National Drug Treatment Monitoring System (NDTMS) 1 April 2008-2031 March 2009. NTA, 2009.
6. Smith N. High potency cannabis: the forgotten variable. Addiction 2005;100:1558-1559
7. Henry JA, Oldfield WLG, Kon OM. Comparing cannabis with tobacco. BMJ 2003;326:942-943
8. Taylor DR, Fergusson DM, Milne BJ, Horwood LJ, Moffitt TE, Sears MR, et al. A longitudinal study of the effects of tobacco and cannabis exposure on lung function in young adults. Addiction 2002;97: 1055-1061
9. Aldington S, Williams M, Nowitz M, Weatherall M, Pritchard A, McNaughton A, et al. Effects of cannabis on pulmonary structure, function and symptoms. Thorax 2007;62:1058-1063 (Pubitemid 350206197)
10. Tan WC, Lo C, Jong A, FitzGerald MJ, Vollmer WM, Buis SA, et al. Marijuana and chronic obstructive lung disease: a population-based study. CMAJ 2009;180:814-820
11. Aldington S, Harwood M, Cox B, Weatherall M, Beckert L, Hansell A, et al. Cannabis use and risk of lung cancer: a case-control study. Eur Respir J 2008;31:280-286
12. Moore THM, Zammit S, Lingford-Hughes A, Barnes TRE, Jones PB, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007;370:319-328 (Pubitemid 47094993)
13. Verdoux H, Ginde C, Sorbora F, Tournier M, Swendsen J. Effects of cannabis and psychosis vulnerability in daily life: an experience sampling study. Psychol Med 2003;33:3-6.
14. Sugranyes G, Flamarique I, Parellada E, Baeza I, Goti J, Fernandez-Egea E, et al. Cannabis use and age of diagnosis of schizophrenia. Eur Psychiatry 2009;24:282-286
15. Zammit S, Moore TH, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, et al. Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry 2008;193:357-363
16. Crippa JA, Zuardi AW, Martín-Santos R, Bhattacharyya S, Atakan Z, McGuire P, et al. Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol 2009;24:515-523
17. Winstock AR, Lea T, Copeland J. Lithium carbonate in the management of cannabis withdrawal. J Psychopharmacol 2009;23:84-93.
18. Yücel M, Solowij N, Respondek C, Whittle S, Fornito A, Pantelis C, et al. Regional brain abnormalities associated with long-term heavy cannabis use. Arch Gen Psychiatry 2008;65:694-701. (Pubitemid 351787240)
19. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, et al. Cognitive functioning of long-term heavy cannabis users seeking treatment [published correction: JAMA 2002;287:1651]. JAMA 2002;287:1123-1131
20. Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry 2004;161:1967-1977 (Pubitemid 39441395)
21. Miller WR, Rollnick S. Motivational interviewing: preparing people for change. Guilford Press, 2002.
22. Copeland J, Frewen A, Elkins K. Management of cannabis use disorder and related issues. A clinician's guide. National Cannabis Prevention and Information Centre, 2009.
23. McCambridge J. Strang J. The efficacy of single-session motivational interviewing in reducing drug consumption and perceptions of drug-related risk and harm among young people: results from a multi-site cluster randomised trial. Addiction 2006;99:39-52. (Pubitemid 38142222)
24. Litt MD, Kadden RM, Kabela-Cormier E, Petry NM. Coping skills training and contingency management treatments for marijuana dependence: exploring mechanisms of behaviour change. Addiction 2008;103:638-648 (Pubitemid 351389279)
25. Moore BA, Budney AJ. Tobacco smoking in marijuana dependent outpatients. J Subst Abuse 2001;3:585-588
26. Vandrey R, Haney M. Pharmacotherapy for cannabis dependence: how close are we? CNS Drugs 2009;23:543-553
27. Budney AJ, Vandrey RG, Hughes JR, Moore BA, Bahrenburg B. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alc Depend 2007;86:22-29 (Pubitemid 44708528)
28. Haney M, Ward AS, Comer SD, Hart CL, Foltin RW, Fischman MW. Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacology 2001;155:171-179 (Pubitemid 32417826)
29. ASH Scotland, Health Scotland, Scottish Drugs Forum, West Lothian Drug and Alcohol Service. Fags 'n' hash: the essential guide to cutting down the risks of using tobacco and cannabis. Health Scotland, 2008.